Biotech Startups

Aikium combines deep learning with large-scale wet-lab experimentation to design and screen protein libraries, aiming to develop protein therapeutics for hard-to-treat targets such as GPCRs and ion channels. The company focuses on drug discovery for parts of the human proteome that conventional antibodies and small molecules cannot address.

4 investors

Clinical-stage biopharmaceutical company developing novel inhaled therapies for COPD.

4 investors

Ajax Therapeutics is a biotech company developing Type II JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis, using computational chemistry and structural biology in its drug discovery. Its lead candidate, AJ1-11095, is in a Phase 1 clinical trial for patients who have failed currently available Type I JAK2 inhibitors.

4 investors

Alamar Biosciences develops NULISA, an ultra-high-sensitivity, high-specificity technology for analyzing hundreds of protein biomarkers from small biofluid samples, building on the team's prior spatial genomics work (RNAscope). The company serves proteomics research and clinical drug development applications.

4 investors

Albus Health develops clinically validated monitoring technology that tracks respiratory metrics, heart rate, and cough frequency to support clinical studies. Its team includes clinicians, respiratory and sleep researchers, biomedical engineers, and computer scientists serving the clinical research and medical technology field.

4 investors

Alden Scientific is a biotech company with over 40 scientists, bioinformaticians, engineers, clinicians, and researchers developing immunological research capabilities. The company operates across Cambridge, Massachusetts and Dortmund, Germany.

4 investors

Alesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology. The biotech company works on early-stage drug development and clinical research.

4 investors

Alida Biosciences develops tools for RNA modification detection and analysis that enable research and diagnostic applications across drug discovery, clinical testing, and biotechnology. The company uses protein engineering and enzymology expertise to enable evaluation of RNA code beyond its primary sequence.

4 investors

ALKemist Bio develops immunotherapies targeting the ALK oncogene in cancer by engineering autologous T cells with synthetic receptors to recognize and eliminate ALK-positive tumor cells. The company's approach aims to address ALK-driven cancers including lymphoma, neuroblastoma, and non-small cell lung cancer.

4 investors

Alkeus Pharma develops therapies for retinal diseases, including inherited and neovascular conditions. The company focuses on gene therapies and other advanced treatment modalities for ophthalmology.

4 investors

Alleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).

4 investors

Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches. The company aims to expand CAR T treatment access through scalable manufacturing, lower costs, and faster treatment delivery.

4 investors

Alpine Bio develops and commercializes functional proteins and bioactive ingredients for food, nutrition, and health applications, targeting formulators who need performance, supply reliability, and clean-label positioning. It uses molecular farming to express target proteins in soybeans along with proprietary purification processes to produce high-purity ingredients.

4 investors

Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic. It focuses on hard-to-drug cancer targets such as mutant KRAS and mutant AKT E17K across malignancies including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancers.

4 investors

Aluna Data provides a benchmarking suite for oncology AI models, offering standardized datasets including over 2 million whole slide images across 25+ tumor types with pathologist annotations, whole genome sequencing data, and clinical information for cancer research and AI development.

4 investors

Amber Bio is a biotechnology company developing a novel RNA writing platform capable of multi-kilobase gene edits that can treat multiple mutations across patients with a single product.

4 investors

American Gene Technologies develops gene therapy treatments for serious diseases including HIV, phenylketonuria, and liver cancer, using a proprietary platform approach designed to accelerate drug development and reduce costs.

4 investors

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins. The company designs degraders that combine favorable properties of PROTAC and molecular glue approaches to address a wider range of tissues and disease indications.

4 investors

Developing broad-spectrum antifungal agents for invasive fungal infections. (Acquired by Pfizer)

4 investors

Biopharmaceutical company discovering and developing novel biologics, protein, and peptide therapeutics.

4 investors

Amylyx is a biopharmaceutical company developing novel therapies for diseases with high unmet medical needs. It focuses on solving difficult medical challenges for affected patients and their families.

4 investors

Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells. The company is a late-stage preclinical biotech focused on precision biologics for immune-mediated disease.

4 investors

Angiex develops Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, using a platform that delivers chemotherapeutic payloads to the nucleus of tumor cells and tumor blood vessel endothelial cells. Its lead asset, AGX101, is a TM4SF1-directed ADC in Phase 1 clinical development for advanced solid tumors.

4 investors

Angle was a cryptocurrency protocol that issued stablecoin tokens (USDA and EURA) that could be redeemed 1:1. The protocol is shutting down with a redemption deadline of March 1, 2027.

4 investors